Please ensure Javascript is enabled for purposes of website accessibility

Why Cassava Sciences Stock Soared Today

By Keith Speights – Jun 21, 2021 at 3:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors applauded the company's update on its clinical programs.

What happened

Shares of Cassava Sciences (SAVA -2.90%) soared 12.6% on Monday. The solid gain came after the company provided a clinical update on several programs. 

So what

With Biogen recently winning U.S. Food and Drug Administration (FDA) approval for Aduhelm in treating Alzheimer's disease, investors are keenly focused on any progress with other programs targeting the disease. Cassava's progress report, which came on a day when the overall stock market delivered a strong performance, was enough to serve as a solid catalyst for the biotech stock.

Alzheimer's Disease printed at the top of a form that's next to X-ray images, a pen, syringes, and pills.

Image source: Getty Images.

Cassava announced that it has completed patient enrollment in an open-label study evaluating simufilam in treating Alzheimer's disease. The company plans to report interim results from the first 50 patients to complete nine months of treatment in the study at the 2021 Alzheimer's Association International Conference scheduled for July 26 through July 30.

In addition, the drugmaker stated that as of mid-June, around 30 patients have been enrolled in another study evaluating simufilam in treating Alzheimer's disease. This study began in May and is designed to compare the drug's impact on cognition in patients who continue with treatment versus those who discontinue treatment.

Now what

Cassava plans to kick off two pivotal late-stage studies of simufilam in the second half of this year. The company has already selected a clinical research organization to run these studies.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cassava Sciences, Inc. Stock Quote
Cassava Sciences, Inc.
SAVA
$41.82 (-2.90%) $-1.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.